FDx Advisors Inc. trimmed its position in ICON PLC (NASDAQ:ICLR) by 4.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,903 shares of the medical research company’s stock after selling 933 shares during the quarter. FDx Advisors Inc.’s holdings in ICON PLC were worth $2,267,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of ICLR. Koch Industries Inc. grew its holdings in ICON PLC by 17,508.8% in the 2nd quarter. Koch Industries Inc. now owns 666,140 shares of the medical research company’s stock valued at $659,000 after buying an additional 662,357 shares in the last quarter. FMR LLC grew its holdings in ICON PLC by 38.4% in the 2nd quarter. FMR LLC now owns 2,291,005 shares of the medical research company’s stock valued at $224,037,000 after buying an additional 635,950 shares in the last quarter. Janus Henderson Group PLC grew its holdings in ICON PLC by 48.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,068,159 shares of the medical research company’s stock valued at $104,488,000 after buying an additional 348,292 shares in the last quarter. Mckinley Capital Management LLC Delaware grew its holdings in ICON PLC by 2,674.8% in the 2nd quarter. Mckinley Capital Management LLC Delaware now owns 338,520 shares of the medical research company’s stock valued at $33,104,000 after buying an additional 326,320 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in ICON PLC by 71.5% in the 3rd quarter. Principal Financial Group Inc. now owns 768,471 shares of the medical research company’s stock valued at $87,513,000 after buying an additional 320,356 shares in the last quarter. 91.64% of the stock is currently owned by hedge funds and other institutional investors.
ICLR has been the topic of a number of research reports. Zacks Investment Research raised ICON PLC from a “hold” rating to a “buy” rating and set a $131.00 price objective on the stock in a report on Saturday, September 9th. Bank of America Corporation initiated coverage on ICON PLC in a report on Monday, September 11th. They issued a “buy” rating and a $128.00 price objective on the stock. ValuEngine raised ICON PLC from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Jefferies Group LLC reaffirmed a “buy” rating on shares of ICON PLC in a report on Sunday, July 30th. Finally, Mizuho upped their price objective on ICON PLC from $104.00 to $108.00 and gave the company a “neutral” rating in a report on Thursday, July 27th. Four analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. ICON PLC has a consensus rating of “Buy” and an average price target of $120.60.
ICON PLC (NASDAQ:ICLR) traded down $1.55 during trading hours on Friday, hitting $113.81. The stock had a trading volume of 419,300 shares, compared to its average volume of 321,214. The company has a market cap of $6,163.04, a P/E ratio of 21.84, a price-to-earnings-growth ratio of 1.76 and a beta of 0.56. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. ICON PLC has a 1 year low of $73.76 and a 1 year high of $124.48.
ICON PLC (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.03. ICON PLC had a return on equity of 28.42% and a net margin of 16.37%. The business had revenue of $440.30 million during the quarter, compared to the consensus estimate of $438.09 million. During the same period in the prior year, the company earned $1.19 EPS. ICON PLC’s revenue for the quarter was up 4.8% on a year-over-year basis. analysts expect that ICON PLC will post 5.36 EPS for the current fiscal year.
About ICON PLC
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for ICON PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON PLC and related companies with MarketBeat.com's FREE daily email newsletter.